Gastric pentadecapeptide (research)
BPC-157
Stable gastric peptide fragment studied for angiogenic, NO-related, and cytoprotective signalling in animal injury models.
Primary Mechanism of Action
Clinical / Scientific
BPC-157 is a 15-amino-acid sequence derived from body-protection compound research. Preclinical literature describes effects on VEGFR2, FAK-paxillin, and nitric-oxide related healing pathways. There is no established licensed indication; human evidence is limited.
Pathway Targets
VEGF signalling
Scientific explanation
Reported angiogenic pathway interaction in models.
NO signalling
Scientific explanation
Reported endothelial / wound effects in animals.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: VEGF signalling → NO signalling
Mechanistically Relevant Repurposed & Adjunctive Applications
Research peptide context
PreclinicalMechanistic rationale
Catalogued as a research peptide. Mechanistic statements below describe known or pathway biology and do not establish a licensed therapeutic indication.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| VEGFR-related angiogenesis | Experimental modulation | Tissue repair models | Preclinical |
| NO pathway | Experimental modulation | Microvascular tone in models | Preclinical |
In Plain Language
BPC-157 is a short stomach-related peptide studied in animals for healing and blood-vessel signals. That is not the same as an approved human medicine.
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.